Business Wire

GORE® VIABAHN® Endoprosthesis Marks 20 Years of Proven Performance

Del

W. L. Gore & Associates, Inc. (Gore) is celebrating the 20th anniversary of the introduction of the GORE® VIABAHN® Endoprosthesis, the market-leading stent-graft for the treatment of complex peripheral vascular disease. The device has been engineered to effectively cover and seal off diseased tissue, providing an endoluminal bypass option for physicians faced with complex, challenging lesions. Since the first implant in Europe in 1996, the device formerly known as the GORE® HEMOBAHN® Endoprosthesis has continuously evolved, now offering CBAS Heparin Surface, lengths up to 25 cm, radiopaque markers, a low profile design, and multiple indications for use. The GORE VIABAHN Endoprosthesis is backed by an ever-growing body of clinical data, including nine randomized or prospective multicenter studies. This continued device evolution and extensive body of clinical proof have enabled the GORE VIABAHN Endoprosthesis to become many physicians’ go-to device for their most challenging cases, selling more than 700,000 units worldwide since its launch.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160907005060/en/

GORE® VIABAHN® Endoprosthesis (Photo: Business Wire)

GORE® VIABAHN® Endoprosthesis (Photo: Business Wire)

“The original introduction of the GORE VIABAHN Endoprosthesis as the first SFA stent-graft with proven patency demonstrated the potential of endoluminal bypass. Since then, the expanded clinical indications for use and product improvements have helped me to achieve positive results in patients with complex disease where often, no other therapy is appropriate and able to achieve good clinical long-term results,” said Prof. Johannes Lammer, MD, former Director of Cardiovascular and Interventional Radiology, AKH - Wien, Medical University Vienna, Vienna, Austria, one of the earliest users of the device.

The GORE VIABAHN Endoprosthesis is the only stent or stent-graft to receive U.S. Food and Drug Administration approval for use in the superficial femoral artery (SFA) (including de novo or restenotic lesions and in-stent restenosis of bare metal stents), iliac artery, and arteriovenous (AV) access. The GORE VIABAHN Endoprosthesis portfolio spans a wide variety of sizes, including the recently added 7.5 cm and 25 cm length versions, the industry’s longest such device. The dynamic range of options allows physicians to effectively cover complex lesions in the most challenging clinical situations.

“In the ever-evolving field of interventional medicine, we can’t rely as much on rule-of-thumb and past experiences. Clinical practice is continually refined as new device and procedure options are introduced to the market. We need rigorous clinical trials to gauge the efficacy of devices in a real-world patient population. Throughout the years, Gore has continued to evaluate the GORE VIABAHN Endoprosthesis in challenging, real-world cases, such as long lesions, AV access outflow stenosis, and in-stent restenosis in the SFA, progressing our treatment options in these very complex cases,” said Richard R. Saxon, MD, FSIR, Director of Research, SDCVI, San Diego Imaging Medical Group, San Diego, CA.

Later this month, in conjunction with the Vascular Interventional Advances 2016 (VIVA) Conference in Las Vegas, Gore will release new data from the most recent clinical study on the device’s performance in treating long, complex lesions in the SFA. Prof. Takao Ohki, MD, PhD, of the Jikei University School of Medicine in Tokyo, Japan, will be presenting 12-month results from the GORE VIABAHN Endoprosthesis Japanese Investigational Device Exemption (IDE) Clinical Study on Tuesday, September 20, at a sponsored breakfast symposium. More information about the GORE VIABAHN Endoprosthesis and the study results to be presented at VIVA 2016 can be found here: https://www.goremedical.com/viabahn-patency.

“During the last two decades, we have seen stent-grafts progress to become a primary treatment option for complex peripheral vascular disease. From the introduction of the endoluminal bypass to the market in 1996, Gore has worked in partnership with the endovascular community to innovate, developing smaller profiles, a thromboresistant surface, and new lengths and diameters, all of which help improve patient outcomes,” said Ray Swinney, Peripheral Interventional Business Unit Leader at Gore.

The GORE VIABAHN Endoprosthesis is constructed with a biocompatible, durable, reinforced, expanded polytetrafluoroethylene (ePTFE) liner. Its flexible design enables the device to traverse tortuous anatomies and provide durable outcomes in complex disease. The device is also available with CBAS Heparin Surface, the proven, lasting heparin bonding technology designed to resist thrombus formation.

Products listed may not be available in all markets. GORE®, HEMOBAHN®, and VIABAHN® are trademarks of W. L. Gore & Associates. CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.

ABOUT W. L. GORE & ASSOCIATES

At Gore, we have provided creative therapeutic solutions to complex medical problems for 40 years. During that time, 40 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984.

Contact information

Chempetitive Group for W. L. Gore & Associates
Andrea Vuturo, +1 (858) 457-2436
GoreMedical@Chempetitive.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The Meet Group Announces Closing of Lovoo Acquisition19.10.2017 20:58Pressemelding

The Meet Group, Inc. (NASDAQ: MEET), a public market leader in the mobile meeting space, has completed its acquisition of Lovoo GmbH. The LOVOO app is the most downloaded dating app in Germany, Switzerland, and Austria combined. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006572/en/ The Meet Group anticipates this purchase will continue the momentum of its mission to meet the universal need for human connection through innovating, acquiring, and building the largest mobile portfolio of brands for meeting new people. The acquisition is expected to expand The Meet Group’s global footprint, increase the company’s scale and profitability, and diversify its business model by adding expertise in subscription and in-app purchasing. “LOVOO is our third strategic acquisition in the last 12 months, and

Edgewater Networks Announces SD-WAN Optimized for BroadSoft Platforms19.10.2017 20:00Pressemelding

Edgewater Networks, Inc., the market leader in Network Edge Orchestration, announces the upcoming availability of its SD-WAN offering targeted for Small to Medium Enterprises, a key market for service providers offering Unified Communications as a Service. Edgewater Networks’ SD-WAN solution is optimized for the BroadSoft BroadWorks® and BroadCloud® platforms and brings the benefits of this technology to the BroadSoft customer base. “As a new component of our Network Edge Orchestration platform, Edgewater Networks SD-WAN service allows BroadSoft customers to offer comprehensive end user service level agreements by ensuring that real-time communications are automatically routed to the best available Internet connection,” said Chris Kolstad, Edgewater Networks’ Vice President of Product Management. “Edgewater Networks’ SD-WAN offers a new revenue stream to service providers with a soluti

Business Wire Receives Type 2 SOC 2 Attestation Engagement Report Related to Security19.10.2017 19:20Pressemelding

Business Wire today announced that it has successfully completed a Type 2 SOC 2 examination of its BW Connect and HQ systems. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006400/en/ The attestation engagement report, conducted by the independent CPA firm Schellman & Company, LLC, confirms that Business Wire has met the standards established by the American Institute of Certified Public Accountants [AICPA] Trust Services Principles related to security. BW Connect is Business Wire’s proprietary web-based order-entry system; HQ provides web-hosting services for online newsrooms, and investor relations hubs for publicly-traded companies. The examination, conducted during the review period February 1, 2017 through July 31, 2017, focused on Business Wire adherence to the Trust Service Principle/Secu

Pharnext: First-Half 201719.10.2017 17:30Pressemelding

Regulatory News: Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced its first-half 2017 financial results. Daniel Cohen, M.D., Ph.D. Co-Founder and CEO said of activity for the first half of 2017: "Activity in the first-half of the year was very dense; we implemented two prominent strategic partnerships with the biotech company Galapagos and the Tasly Group, one of the top ten pharmaceutical companies in China. Our flagship product, PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A, is nearing the end of Phase 3, which is slated for the second half of 2018. We confirm our target of taking the product to market by 2019." A half-year marked by strategic agreements

Tickets Now on Sale for FEI World Equestrian Games Tryon 2018, North Carolina, USA, on September 11-23, 201819.10.2017 16:58Pressemelding

Tickets for the FEI World Equestrian GamesTM Tryon 2018 (WEG) are now on sale to the public online at www.tryon2018.com. With more than 500,000 people expected to attend the 2018 Games, the 12-day spectacle of equestrian champions is one of the biggest events on the global sporting calendar and will be the largest equestrian event in North Carolina’s history. Mark Bellissimo, CEO of host venue Tryon International Equestrian Center (TIEC) in Tryon, NC, USA, said: “Demand from the event is way beyond our expectations and it would not surprise me if this event were to sell out early. We have experienced unprecedented demand, far bigger than we ever anticipated. There is tremendous appetite for this event, so we encourage people to buy now.” Tickets for the WEG include the following options: a standard Day Pass, Individual Event Pass, All Session Discipline Pas

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom